U.S. taxpayers have already paid for the research and testing of the most promising treatments
There’s much we don’t yet know about COVID-19, the disease caused by the novel coronavirus. We don’t know how long the pandemic will last, when a vaccine will be developed, or how many lives antiviral medications can save. But there’s one thing we know for sure: U.S. taxpayers have already paid for the research and testing of the most promising treatments.
These treatments should be available to everyone who needs them at no cost. But the Trump administration’s drug policy is led by two former pharmaceutical executives, and that is having devastating consequences for potential access to treatments and vaccines for the COVID-19 pandemic.
If you’ve been watching Donald Trump’s daily press briefings, that might come as a surprise. During his 2016 campaign, Trump loved to talk tough on pharma and say he would fight for lower drug prices. But then he put Alex Azar, a big pharma CEO infamous for doubling the price of insulin, in charge of regulating health care. Several weeks ago, Azar refused to guarantee that a coronavirus vaccine will be affordable for all, citing the need to protect big pharma’s profits.